Cancer could be detected three years before diagnosis with experimental blood analysis

Johns Hopkins University researchers say they have discovered an advanced method to detect cancer.

A new study, published in Cancer Discovery and partially financed by the National Health Institutes, found that the genetic material spilled by tumors can be detected in the bloodstream three years before a cancer diagnosis.

The researchers analyzed plasma samples of a risk study of large atherosclerosis in the communities (Aric) to evaluate the risk factors of heart attack, stroke, heart failure and other cardiovascular diseases, according to a press release.

The FDA approves the first AI tool to predict the risk of breast cancer

Blood samples of 26 participants were analyzed that were diagnosed with cancer within six months after sampling, and 26 that were not diagnosed with cancer.

Of these 52 participants, eight obtained positive scores in a multi -cancer early detection laboratory test (MCED) and were diagnosed with cancer within four months after blood collection.

MCED tests are an experimental type of cancer detection that seeks signs of multiple types of cancer at the same time, according to the American Cancer Society.

These signs may include DNA pieces, RNA or abnormal cell proteins.

Click here to register in our health newsletter

For six of these eight individuals, researchers were able to evaluate additional blood samples that were collected from 3.1 to 3.5 years before diagnosis.

In four samples, the researchers identified mutations derived from tumors (genetic alterations within cancer cells).

The main author of the Yuxuan Wang study, MD, Ph.D., Assistant Professor of Oncology at the Johns Hopkins University Faculty, shared in a statement that the researchers were surprised by the results.

“Three years before it provides time for the intervention,” he said. “Tumors are likely to be much less advanced and more likely to be curable.”

For more health articles, visit www.Newsnews.com/health

Senior study author Bert Vogelstein, MD, Clayton’s Oncology professor and co -director of the Ludwig Center in Johns Hopkins, said the study shows “the promise of the MCE tests to detect very early cancers, and establishes the reference sensibilities required for its success.”

Cancer detection years before a clinical diagnosis could help “provide the management of a more favorable result,” said principal author Nickolas Papadopoulos, Ph.D., professor of oncology and researcher at the Ludwig Center.

Click here to get the News application

“Of course, we need to determine the appropriate clinical monitoring after a positive test for such cancers,” he added.

News Digital contacted Johns Hopkins to comment.